Justin Smith
Stock Analyst at Bernstein
(4.45)
# 1,185
Out of 5,125 analysts
166
Total ratings
70.1%
Success rate
10.2%
Average return
Main Sectors:
Stocks Rated by Justin Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EPA: SAN Sanofi | Reiterated: Buy | €106.21 → €110.00 | €85.95 | +27.98% | 6 | Nov 4, 2026 | |
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 19,800p → 20,500p | 13,884p | +47.65% | 39 | Nov 3, 2026 | |
| LON: GSK GSK plc | Reiterated: Buy | 3,010p → 3,004p | 1,917p | +56.70% | 27 | Nov 2, 2026 | |
| SWX: NOVN Novartis AG | Reiterated: Hold | CHF 133.00 → CHF 127.08 | CHF 134.48 | -5.50% | 3 | Oct 29, 2026 | |
| SWX: ROP Roche Holding AG | Reiterated: Buy | CHF 434.50 | CHF 401.80 | +8.14% | 27 | Oct 6, 2026 | |
| SWX: SFZN Siegfried Holding AG | Reiterated: Buy | n/a | $71.50 | - | 1 | Sep 14, 2026 | |
| ETR: MRK Merck KGaA | Reiterated: Hold | €112.00 → €151.00 | €149.35 | +1.10% | 2 | Aug 7, 2026 | |
| SWX: LONN Lonza Group AG | Reiterated: Buy | n/a | $661.00 | - | 9 | Jul 24, 2026 | |
| NVS Novartis AG | Initiated Coverage: Hold | n/a | $163.30 | - | 1 | Mar 19, 2026 | |
| GMAB Genmab | Reiterated: Sell | n/a | $54.09 | n/a | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $29.36 | n/a | 8 | Aug 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | €10.50 → €2.90 | €0.79 | n/a | 3 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €22.00 → €21.50 | €11.38 | n/a | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $85 → $51 | $62.78 | n/a | 10 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $104 | $148.04 | n/a | 4 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | €45.80 → €71.00 | €40.72 | n/a | 7 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €69.00 → €70.00 | €53.47 | n/a | 6 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $61.08 | n/a | 2 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $172 → $140 | $293.91 | n/a | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $51.24 | n/a | 1 | Sep 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $15.01 | n/a | 1 | Nov 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $22.74 | n/a | 1 | Feb 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $78 | $1,433.04 | n/a | 1 | Apr 7, 2016 |
Sanofi
Nov 4, 2026
Reiterated: Buy
Price Target: €106.21 → €110.00
Current: €85.95
Upside: +27.98%
AstraZeneca PLC
Nov 3, 2026
Reiterated: Buy
Price Target: 19,800p → 20,500p
Current: 13,884p
Upside: +47.65%
GSK plc
Nov 2, 2026
Reiterated: Buy
Price Target: 3,010p → 3,004p
Current: 1,917p
Upside: +56.70%
Novartis AG
Oct 29, 2026
Reiterated: Hold
Price Target: CHF 133.00 → CHF 127.08
Current: CHF 134.48
Upside: -5.50%
Roche Holding AG
Oct 6, 2026
Reiterated: Buy
Price Target: CHF 434.50
Current: CHF 401.80
Upside: +8.14%
Siegfried Holding AG
Sep 14, 2026
Reiterated: Buy
Price Target: n/a
Current: $71.50
Upside: -
Merck KGaA
Aug 7, 2026
Reiterated: Hold
Price Target: €112.00 → €151.00
Current: €149.35
Upside: +1.10%
Lonza Group AG
Jul 24, 2026
Reiterated: Buy
Price Target: n/a
Current: $661.00
Upside: -
Novartis AG
Mar 19, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $163.30
Upside: -
Genmab
Sep 8, 2025
Reiterated: Sell
Price Target: n/a
Current: $54.09
Upside: n/a
Aug 17, 2025
Reiterated: Hold
Price Target: n/a
Current: $29.36
Upside: n/a
Mar 31, 2025
Downgraded: Hold
Price Target: €10.50 → €2.90
Current: €0.79
Upside: n/a
Dec 10, 2024
Reiterated: Buy
Price Target: €22.00 → €21.50
Current: €11.38
Upside: n/a
Mar 11, 2024
Downgraded: Hold
Price Target: $85 → $51
Current: $62.78
Upside: n/a
Mar 11, 2024
Downgraded: Sell
Price Target: $104
Current: $148.04
Upside: n/a
Nov 17, 2023
Upgraded: Buy
Price Target: €45.80 → €71.00
Current: €40.72
Upside: n/a
Nov 17, 2023
Reiterated: Buy
Price Target: €69.00 → €70.00
Current: €53.47
Upside: n/a
Feb 27, 2023
Upgraded: Buy
Price Target: n/a
Current: $61.08
Upside: n/a
Nov 8, 2022
Downgraded: Hold
Price Target: $172 → $140
Current: $293.91
Upside: n/a
Sep 3, 2019
Upgraded: Buy
Price Target: n/a
Current: $51.24
Upside: n/a
Nov 12, 2018
Reiterated: Buy
Price Target: n/a
Current: $15.01
Upside: n/a
Feb 24, 2017
Downgraded: Hold
Price Target: n/a
Current: $22.74
Upside: n/a
Apr 7, 2016
Initiated Coverage: Hold
Price Target: $78
Current: $1,433.04
Upside: n/a